[1] KILLICK S B, BOWN N, CAVENAGH J,et al. Guidelines for the diagnosis and management of adult aplastic anaemia[J]. Br J Haematol, 2016,172(2):187-207.
[2] CONTEJEAN A, RESCHE-RIGON M, TAMBURINI J, et al. Aplastic anemia in the elderly: a nationwidesurvey on behalf of the French Reference Center for Aplastic Anemia[J]. Haematologica, 2019, 104(2):256-262.
[3] LOCASCIULLI A, BACIGALUPO A, BRUNO B, et al. Hepatitis-associated aplastic anaemia: epidemiology and treatment results obtained in Europe. A report of the EBMT aplastic anaemia working party[J]. Br J Haematol, 2010, 149(6):890-895.
[4] 付蓉.再生障碍性贫血诊断与治疗中国专家共识(2017年版)[J].中华血液学杂志,2017,38(1):1-5.
[5] VAHT K, GÖRANSSON M, CARLSON K, et al. Incidence and outcome of acquired aplastic anemia: real-world data from patients diagnosed in Sweden from 2000-2011[J]. Haematologica, 2017, 102(10):1683-1690.
[6] BACIGALUPO A, ONETO R, SCHREZENMEIER H,et al. First line treatment of aplastic anemia with thymoglobuline in Europe and Asia: outcome of 955 patients treated 2001-2012[J]. Am J Hematol, 2018, 93(5):643-648.
[7] ALSHAIBANI A, DUFOUR C, RISITANO A, et al. Hepatitis-associated aplastic anemia[J]. Hematol Oncol Stem Cell Ther, 2022,15(2):8-12. |
